M. Michallet

E. Wattel, X. Thomas, C. Rioufol, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High burden of BK virus-associated hemorrhagic cystitis in patients undergoing allogeneic hematopoietic stem cell transplantation

G. Salles, X. Thomas, F. Barraco, 2014, Bone Marrow Transplantation.

Defining the clinical condition of cancer patients: it is time to switch from performance status to nutritional status

E. Lemarié, W. Cacheux, O. Mir, 2011, Supportive Care in Cancer.

Research protocol on early palliative care in patients with acute leukaemia after one relapse

C. Barbaret, Stéphane Sanchez, M. Filbet, 2017, BMJ Supportive & Palliative Care.

A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule

X. Thomas, M. Elhamri, F. Barraco, 2010, Hematology.

of the Intergroupe Francophone du Myélome Genetic abnormalities and survival in multiple myeloma: the experience

R. Bataille, B. Grosbois, I. Yakoub-Agha, 2011 .

Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire

J. Soulier, I. Yakoub-Agha, D. Blaise, 2011, Haematologica.

Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire

J. Soulier, I. Yakoub-Agha, D. Blaise, 2009 .

Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

A. Ganser, N. Kröger, M. Labopin, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Mobilization of CD34(+)CD38(-) hematopoietic stem cells after priming in acute myeloid leukemia.

A. Plesa, C. Dumontet, X. Thomas, 2013, World journal of stem cells.

photopheresis for treatment of chronic graft-versus-host disease A multicenter prospective phase 2 randomized study of extracorporeal

L. Bouzas, A. Elmaagacli, R. Knobler, 2013 .

A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease.

L. Bouzas, D. Parenti, A. Elmaagacli, 2008, Blood.

Using EasyMatch® to anticipate the identification of an HLA identical unrelated donor: A validated efficient time and cost saving method.

X. Thomas, Y. Bertrand, F. Barraco, 2016, Human immunology.

Late autologous transplantation in chronic myelogenous leukemia with peripheral blood progenitor cells mobilized by G-CSF and interferon-α

C. Vigouroux, C. Dumontet, X. Thomas, 2000, Leukemia.

Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial

J. Reiffers, G. Marit, D. Maraninchi, 1989, British journal of haematology.

Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005–01 trial

B. Pégourié, S. Leyvraz, P. Moreau, 2010, Leukemia.

Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: report from the European Cooperative Group for bone marrow transplantation (8 cases).

A. Gratwohl, A. Domingo, B. Corront, 1988, Nouvelle revue francaise d'hematologie.

All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.

H. Dombret, A. Vekhoff, E. Wattel, 2002, The hematology journal : the official journal of the European Haematology Association.

Autologous and Allogeneic Transplantations for Chronic Lymphocytic Leukemia

M. Michallet, 2004 .

Effect of priming with granulocyte–macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group

J. Bourhis, H. Dombret, B. Quesnel, 2007, Leukemia.

Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and

M. Labopin, I. Yakoub-Agha, H. Sengeløv, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML)

D. Auboeuf, M. Thénoz, E. Wattel, 2015, Oncotarget.

Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias.

E. Gilson, E. Wattel, C. Preudhomme, 2011, Experimental hematology.

M. Michallet, C. Losem, 2015, Acta Haematologica.

N. Kröger, J. Sierra, M. Robin, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM)

A. Fischer, J. Reiffers, N. Ifrah, 1997, British journal of haematology.

Impact of anti-HLA antibodies on allogeneic hematopoietic stem cell transplantation outcomes after reduced-intensity conditioning regimens.

X. Thomas, F. Barraco, F. Nicolini, 2012, Experimental hematology.

[Use of alternative donors for allogeneic haematopoietic cell transplantation in lymphoid neoplasms: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

G. Salles, I. Yakoub-Agha, F. Morschhauser, 2017, Bulletin du Cancer.

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP)

J. Cayuela, C. Preudhomme, M. Tulliez, 2006, Leukemia.

Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.

D. Blaise, M. Mohty, V. Bardou, 2004, Blood.

Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008).

R. Porcher, M. Mohty, G. Socié, 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies.

E. Kimby, E. Montserrat, S. Stilgenbauer, 2018, Blood.

Systemic antifungal strategies in allogeneic hematopoietic stem cell recipients hospitalized in french hematology units: a post-hoc analysis of the cross-sectional observational AFHEM study

I. Yakoub-Agha, R. Herbrecht, J. Gangneux, 2022, BMC Infectious Diseases.

Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT

J. Esteve, A. Ganser, M. Labopin, 2019, Haematologica.

Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)

M. Robin, P. Chevallier, I. Yakoub-Agha, 2014, Bone Marrow Transplantation.

Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients

P. Vanhems, X. Thomas, F. Persat, 2011, European Journal of Clinical Microbiology & Infectious Diseases.

Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study.

J. Bourhis, H. Dombret, B. Quesnel, 2011, Blood.

Minimally differentiated acute myeloid leukemia (FAB AML-M0): prognostic factors and treatment effects on survival--a retrospective study of 42 adult cases.

A. Plesa, C. Dumontet, X. Thomas, 2011, Leukemia research.

Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia

H. Tilly, D. Blaise, J. Reiffers, 1997, Bone Marrow Transplantation.

Systemic Antifungal Prophylaxis in Patients Hospitalized in Hematology Units in France: The AFHEM Cross-Sectional Observational Study

I. Yakoub-Agha, R. Herbrecht, J. Gangneux, 2018, Infectious Diseases and Therapy.

Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation

C. Preudhomme, M. Tulliez, S. Hayette, 2007, Haematologica.

Major Molecular Response Achievement in CML Patients Can Be Predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS Ratio at an Earlier Time Point of Follow-Up than Currently Recommended

P. Cony-Makhoul, J. Magaud, S. Hayette, 2014, PloS one.

The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge.

J. Magaud, S. Hayette, I. Tigaud, 2010, Clinical lymphoma, myeloma & leukemia.

BCR-ABLT315I transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?

J. Cassuto, S. Hayette, J. Magaud, 2007, Leukemia.

BCR-ABL mutant kinetics in CML patients treated with dasatinib.

J. Magaud, S. Hayette, I. Tigaud, 2007, Leukemia research.

Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients.

J. Magaud, S. Hayette, F. Nicolini, 2005, Leukemia research.

Identification of a rare e6a2 BCR-ABL fusion gene during the disease progression of chronic myelomonocytic leukemia: a case report

X. Thomas, S. Hayette, I. Tigaud, 2004, Leukemia.

Secondary Philadelphia chromosome after non-myeloablative peripheral blood stem cell transplantation for a myelodysplastic syndrome in transformation

S. Hayette, A. Thiébaut, C. Charrin, 2004, Bone Marrow Transplantation.

A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.

J. Reiffers, P. Berthaud, P. Hurteloup, 1996, Leukemia.

Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.

P. Fenaux, X. Thomas, X. Troussard, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic bone marrow transplantation remains an efficient consolidation for adults with acute myeloid leukemia even when performed very soon after diagnosis (< 100 days). The SFGM (Société Française de Greffe de Moelle.

J. Reiffers, E. Archimbaud, N. Ifrah, 1995, Leukemia.

Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis

D. Olive, D. Blaise, V. Leblond, 1995, The Lancet.

Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse [see comments]

D. Blaise, J. Reiffers, E. Archimbaud, 1992 .

Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy

H. Dombret, A. Vekhoff, P. Fenaux, 2005, Leukemia & lymphoma.

Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors

X. Thomas, M. Elhamri, Q. Le, 2003, Annals of Hematology.

Impact of Azacitidine (AZA) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) for Myelodysplastic Syndromes (MDS): A Large-Scale Study on Behalf of the SFGM-TC and GFM Groups

M. Robin, I. Yakoub-Agha, M. Mohty, 2011 .

Potential anti-leukemic activity of iron chelation after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia

X. Thomas, F. Barraco, F. Nicolini, 2017, Leukemia and Lymphoma.

Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia

H. Dombret, H. Tilly, C. Bastard, 2005, Bone Marrow Transplantation.

Autologous stem cell transplantation versus chemotherapy for adult patients with acute myeloid leukemia in first remission: the BGMT Group experience.

P. Cony-Makhoul, D. Blaise, J. Reiffers, 1993, Nouvelle revue francaise d'hematologie.

Improved relapse‐free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: Lessons from the randomized European Society for Blood and Marrow Transplantation‐Intergroup study

N. Kröger, D. Niederwieser, P. Dreger, 2014, American journal of hematology.

Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution Experience

G. Salles, A. Plesa, E. Wattel, 2016, Mediterranean journal of hematology and infectious diseases.

Autologous hematopoietic stem cell transplantation for adults with acute myeloid leukemia in complete remission: The Edouard Herriot hospital experience

X. Thomas, M. Elhamri, A. Thiébaut, 2006, Hematology.

Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto‐SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM‐TC

M. Labopin, P. Chevallier, I. Yakoub-Agha, 2015, European journal of haematology.

Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation.

R. Brand, M. Hallek, D. Catovsky, 2011, Blood.

Autologous stem cell transplantation for chronic lymphocytic leukemia.

R. Brand, P. Dreger, M. Michallet, 2007, Seminars in hematology.

5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies

A. Palumbo, H. Dombret, B. Quesnel, 2014 .

Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: A multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

I. Yakoub-Agha, D. Blaise, M. Mohty, 2015, Bone Marrow Transplantation.

Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.

H. Dombret, M. Labopin, M. Mohty, 2014, European journal of cancer.

Impact on outcome of MRD prior hematopoietic stem cell transplantation after FLAMSA-busulfan conditioning regimen: a retrospective monocentric study.

A. Plesa, X. Thomas, S. Hayette, 2022, Transplantation and cellular therapy.

Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia: WE‐S9‐MTP‐030

M. Sobh, M. Michallet, 2018, Clinical Lymphoma Myeloma and Leukemia.

Prognostic Value of Immunophenotyping in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience.

A. Plesa, C. Dumontet, X. Thomas, 2007 .

Reduced-intensity versus myeloablative conditioning in cord blood transplantation for AML (40-60 years) across highly mismatched HLA barriers - On behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT.

J. Sierra, D. Blaise, C. Chabannon, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire.

P. Chevallier, I. Yakoub-Agha, D. Blaise, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial.

J. Bourhis, H. Dombret, B. Quesnel, 2012, Leukemia research.

Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC.

C. Volteau, P. Chevallier, D. Blaise, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Granulocyte colony‐stimulating factor given in addition to interferon‐α to mobilize peripheral blood stem cells for autologous transplantation in chronic myeloid leukaemia

P. Adeleine, C. Charrin, E. Archimbaud, 1997 .

Factors Influencing Outcome in De Novo Myelodysplastic Syndromes Treated by Allogeneic Bone Marrow Transplantation: A Long-Term Study

C. Chastang, X. Troussard, N. Ifrah, 2002 .

Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire

J. Bourhis, M. Bernard, M. Labopin, 2013, European journal of haematology.

e- Blood Myelodysplasia and leukemia of Fanconi anemia are associated with a speciﬁc pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions

F. Sigaux, J. Soulier, A. Baruchel, 2011 .

Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation.

J. Ito, M. Michallet, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential Chemotherapy with Mitoxantrone, Etoposide and Cytarabine for Previously Treated Acute Myeloid Leukemia: EMA 86 Regimen

P. Fenaux, X. Thomas, X. Troussard, 1996 .

Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning

N. Kröger, P. Dreger, M. Karas, 2019, Journal of Cancer Research and Clinical Oncology.

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.

Martin C. Müller, I. Dufva, G. Martinelli, 2011, Blood.

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

Martin C. Müller, I. Dufva, D. Marin, 2013, Haematologica.

The BCR-ABLT 315 I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors , in a matched pair analysis

Martin C. Müller, I. Dufva, D. Marin, 2013 .

Homo-Harringtonine (Omacetaxine mepesuccinate) Induces a Dramatic and Sustained Reduction of BCR-ABLT315I mutated Transcripts in Chronic Phase Chronic Myelogenous Leukemia Patients Resistant to Tyrosine Kinase Inhibitors.

S. Hayette, F. Guilhot, F. Nicolini, 2008 .

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T 315 I mutation

H. Kantarjian, J. Cortes, C. Chuah, 2012 .

Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up

M. Baccarani, H. Kantarjian, J. Cortes, 2015, Cancer.

An EBMT Prospective Non-Interventional Study of Outcomes and Toxicity of Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second Generation Tyrosine Kinase Inhibitors

A. Ganser, N. Kröger, S. Iacobelli, 2016 .

Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy

I. Yakoub-Agha, D. Blaise, M. Mohty, 2015, Bone Marrow Transplantation.

High rate of long‐term survivals in aml treated by chemotherapy and androgenotherapy. A pilot study

J. Sotto, M. Michallet, R. Berthier, 1980 .

Growth factor‐associated graft‐versus‐host disease and mortality 10 years after allogeneic bone marrow transplantation

M. Labopin, M. Mohty, O. Ringdén, 2012, British journal of haematology.

Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose.

R. Brand, A. Gratwohl, D. Niederwieser, 2002, Blood.

Randomized Comparison of Standard Induction with Daunorubicin (DNR) for 3 Days vs Idarubicin (IDA) for 3 or 4 Days in AML pts Aged 50 to 70 and of Maintenance with Interleukin 2. Final Analysis of the ALFA 9801 Study.

J. Bourhis, H. Dombret, S. Chevret, 2007 .

Actinomycosis after allogeneic hematopoietic stem cell transplantation despite penicillin prophylaxis

X. Thomas, F. Barraco, F. Valour, 2016, Transplant infectious disease : an official journal of the Transplantation Society.

Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD.

I. Yakoub-Agha, J. Bay, G. Socié, 2019, Blood advances.

A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD.

I. Yakoub-Agha, J. Bay, Z. Medeghri, 2017, Blood.

Inolimomab in steroid-resistant aGvHD 1 A phase III randomized trial comparing Inolimomab vs . Usual care in steroid-resistant acute GVHD

I. Yakoub-Agha, J. Bay, Z. Medeghri, 2016 .

Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC.

P. Chevallier, I. Yakoub-Agha, D. Blaise, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Randomized study of 2 reduced‐intensity conditioning strategies for human leukocyte antigen‐matched, related allogeneic peripheral blood stem cell transplantation

D. Blaise, M. Mohty, V. Bardou, 2013, Cancer.

O7.3BET-bromodomain (BRD) inhibitor OTX015: Final results of the dose-finding part of a phase I study in hematologic malignancies

A. Palumbo, H. Dombret, P. Hérait, 2015 .

Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia

J. Golmard, M. Béné, A. Plesa, 2017, European journal of haematology.

Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation

D. Blaise, M. Mohty, D. Coso, 2004, Bone Marrow Transplantation.

Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients

P. Moreau, H. Avet-Loiseau, T. Dejoie, 2017, Leukemia.

Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group

P. Richardson, F. Baron, I. Yakoub-Agha, 2019, Bone Marrow Transplantation.

Incidence, Risk Factors, and Long-term Outcome of Acute Leukemia Patients With Early Candidemia After Allogeneic Stem Cell Transplantation: A Study by the Acute Leukemia and Infectious Diseases Working Parties of European Society for Blood and Marrow Transplantation

C. Craddock, A. Nagler, M. Mohty, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation

J. Bourhis, D. Blaise, P. Tiberghien, 2012, Bone Marrow Transplantation.

Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization

V. Maguer-Satta, O. Tournilhac, F. Nicolini, 2008, Leukemia.

Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies

A. Palumbo, H. Dombret, B. Quesnel, 2014 .

[Monitoring of chimerism in myeloid cells sorting of transplanted patients with acute myeloid leukaemia: a study from Lyon (France)].

I. Mollet, D. Rigal, V. Dubois, 2012, Pathologie-biologie.

Sequential chemotherapy followed by reduced‐intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT

A. Ganser, L. Kanz, M. Labopin, 2017, British journal of haematology.

Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

M. Labopin, I. Yakoub-Agha, A. Nagler, 2017, Haematologica.

Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT

M. Labopin, D. Blaise, M. Mohty, 2014, Bone Marrow Transplantation.

Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

M. Labopin, P. Chevallier, I. Yakoub-Agha, 2014, Bone Marrow Transplantation.

Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire

J. Bourhis, M. Labopin, I. Yakoub-Agha, 2010, Leukemia.

Outcome Of Patients With IPSS Intermediate (int) Or High Risk Myelodysplastic Syndrome (MDS) According To Donor Availability: A Multicenter Prospective Non Interventional Study For The SFGM-TC and GFM

R. Porcher, H. Dombret, P. Fenaux, 2013 .

A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study).

C. Sebban, P. Moreau, J. Bay, 2012, European journal of cancer.

[Trial of androgen therapy in the treatment of non-lymphoblastic acute leukemia. First results].

P. Ribaud, J. Sotto, M. Michallet, 1976, La Nouvelle presse medicale.

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

B. Pégourié, O. Decaux, P. Moreau, 2013, Blood.

ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT

J. Esteve, C. Craddock, F. Baron, 2017, American journal of hematology.

Persistence of lymphocyte function perturbations after granulocyte–colony‐stimulating factor mobilization and cytapheresis in normal peripheral blood stem cell donors

E. Deconinck, E. Robinet, P. Tiberghien, 2010, Transfusion.

Inolimomab in Steroid-Refractory Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis and Comparison with Other Interleukin-2 Receptor Antibodies

A. Fischer, A. Stamatoullas, I. Yakoub-Agha, 2005, Transplantation.

Allogeneic bone marrow transplantation in 24 patients with multiple myeloma reported to the ebmt registry

G. Gahrton, A. Gratwohl, O. Ringdén, 1988, Hematological oncology.

Autografting for chronic granulocytic leukemia in transformation.

J. Reiffers, P. Hervé, D. Maraninchi, 1986, Journal of the National Cancer Institute.

Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation.

N. Mahlaoui, Y. Bertrand, A. Thiébaut, 2012, The Journal of antimicrobial chemotherapy.

Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party

N. Kröger, S. Iacobelli, E. Tholouli, 2017, Haematologica.

Generation of helper and cytotoxic CD4+T cell clones specific for the minor histocompatibility antigen H-Y, after in vitro priming of human T cells by HLA-identical monocyte-derived dendritic cells.

H. Vié, J. Even, D. Rigal, 2001, Transplantation.

Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus

R. Ria, L. Trentin, C. Agostini, 2021, European journal of haematology.

Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients

P. Vanhems, X. Thomas, F. Persat, 2012, European Journal of Clinical Microbiology & Infectious Diseases.

Gemtuzumab Ozogamicin (Mylotarg®) as Single Agent Treatment for Adult Patients with Acute Myeloid Leukemia (AML).

X. Thomas, M. Elhamri, A. Thiébaut, 2005 .

[Hepatitis B virus reactivation after allogeneic bone marrow transplantation in a patient previously cured of hepatitis B].

F. Zoulim, C. Trépo, M. Michallet, 1999, Gastroenterologie clinique et biologique.

Autologous transplantation in acute myeloid leukemia: peripheral blood stem cell harvest after mobilization in steady state by granulocyte colony-stimulating factor alone

X. Thomas, I. Philip, Q. Le, 2001, Annals of Hematology.

Acute Graft-Versus-Host Disease: Grade and Outcome in Patients With Chronic Myelogenous Leukemia

P. Bartolomeo, G. Gahrton, J. Hermans, 2000 .

Sequential treatment for allogeneic hematopoietic stem cell transplantation in Fanconi anemia with acute myeloid leukemia

J. Soulier, T. Leblanc, G. Socié, 2014, Haematologica.

Interferon Alpha and Cytosine Arabinoside in the Treatment of Chronic Myelogenous Leukemia

R. Bouabdallah, F. Bauters, N. Ifrah, 1998 .

Bone marrow transplantation in multiple myeloma: report from the European Cooperative Group for Bone Marrow Transplantation.

G. Gahrton, A. Gratwohl, J. Reiffers, 1987, Blood.

Oral cyclosporine A in neonatal swines for transplantation studies

J. Dubernard, A. Gazarian, M. Sobh, 2015, Immunopharmacology and immunotoxicology.

Oral cyclosporine A in neonatal swines for transplantation studies

J. Dubernard, A. Gazarian, M. Sobh, 2015, Immunopharmacology and immunotoxicology.

The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT

S. Montoto, J. Bourhis, N. Kröger, 2019, Annals of Hematology.

Treatment of Relapse After Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndrome: A Large-Scale Study On Behalf of the Société Française De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

M. Robin, I. Yakoub-Agha, D. Blaise, 2012 .

Does more intensive treatment cure more patients with acute myeloid leukemia? The BGMT Group.

J. Reiffers, G. Marit, D. Maraninchi, 1991, Seminars in hematology.

D. Niederwieser, P. Dreger, M. Boogaerts, 2005 .

Transplant Outcome of Unrelated Hematopoietic Stem Cell Transplantation (HSCT) after Myelo-Ablative or Reduced Intensity Conditioning (RIC) for Chronic Lymphocytic Leukemia(CLL). A Study of EBMT Registry.

R. Brand, D. Niederwieser, P. Dreger, 2005 .

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

S. Montoto, N. Kröger, A. Nagler, 2018, Bone Marrow Transplantation.

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation

M. Abecassis, P. Richardson, F. Baron, 2016, Bone Marrow Transplantation.

A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia.

J. Bourhis, H. Dombret, S. Chevret, 2020, Blood.

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.

J. Bourhis, H. Dombret, C. Preudhomme, 2020, Blood advances.

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.

J. Bourhis, H. Dombret, S. Chevret, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of a severe extensive cutaneous chronic GVHD after allo-HSCT using glycerolyzed skin allografts and cultured epidermis from the same donor

O. Damour, V. Dubois, M. Sobh, 2011, Bone Marrow Transplantation.

Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia.

P. Fenaux, E. Archimbaud, V. Leblond, 1991, Blood.

Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation

J. Levron, F. Persat, M. Piens, 1998, Bone Marrow Transplantation.

Itraconazole in the treatment of aspergillosis: a study of 16 cases

B. Lebeau, P. Ambroise‐Thomas, R. Grillot, 1994, Mycoses.

Combined medico‐surgical strategy for invasive sino‐orbito‐cerebral breakthrough fungal infection with Hormographiella aspergillata in an acute leukaemia patient

X. Thomas, J. Saison, C. Chidiac, 2015, Mycoses.

Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009

Antoine Duclos, Stéphane Picot, N. Voirin, 2011, Haematologica.

Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole.

P. Vanhems, X. Thomas, F. Nicolini, 2011, Medical mycology.

Outcomes of Antifungal Prophylaxis in High-Risk Haematological Patients (AML under Intensive Chemotherapy): The SAPHIR Prospective Multicentre Study

A. Pigneux, J. Gangneux, T. Gastinne, 2020, Journal of fungi.

Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status

I. Yakoub-Agha, D. Blaise, M. Mohty, 2020, Bone Marrow Transplantation.

Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT

R. Fanin, M. Labopin, D. Blaise, 2017, Bone Marrow Transplantation.

Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study.

D. Parenti, A. Elmaagacli, K. van Besien, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT)

X. Thomas, S. Hayette, F. Nicolini, 2005, Bone Marrow Transplantation.

Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties

S. Iacobelli, C. Craddock, P. Chevallier, 2016, Bone Marrow Transplantation.

Evaluation of Posaconazole for Primary Prophylaxis of IFI in Acute Myeloid Leukemia under Intensive Induction Chemotherapy. Comparative Real Life Study with Fluconazole in two Hematological Centers in Algeri

M. Michallet, M. Brahimi, N. Yafour, 2021, Asian Pacific Journal of Cancer Biology.

Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system

P. Moreau, R. Herbrecht, B. Dupont, 2011, Journal of medical economics.

Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial

H. Dombret, B. Quesnel, P. Fenaux, 2012, Leukemia & lymphoma.

HHV-6 infection after allogeneic hematopoietic stem cell transplantation: From chromosomal integration to viral co-infections and T-cell reconstitution patterns.

X. Thomas, V. Escuret, F. Barraco, 2016, The Journal of infection.

Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Ce

J. Bourhis, I. Yakoub-Agha, J. Golmard, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trypanosoma-Cruzi Cross-Reactive Antibodies Longitudinal Follow-Up: A Prospective Observational Study in Hematopoietic Stem Cell Transplantation

P. Vanhems, H. Pottel, B. Pozzetto, 2015, PLoS ONE.

Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study.

J. Bourhis, D. Blaise, M. Mohty, 2002, Blood.

Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome.

D. Blaise, P. Moreau, X. Thomas, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle.

J. Bourhis, D. Blaise, J. Moatti, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM)

A. Baruchel, H. Tilly, D. Blaise, 2000, Bone Marrow Transplantation.

First human face allograft: early report

Bernard Devauchelle, Sylvie Testelin, Lionel Badet, 2006, The Lancet.

D. Blaise, J. Reiffers, E. Archimbaud, 1992, Blood.

HSV excretion after bone marrow transplantation: a 4-year survey.

A. Thiébaut, M. Aymard, D. Thouvenot, 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

A new signaling cascade linking BMP4, BMPR1A, ΔNp73 and NANOG impacts on stem-like human cell properties and patient outcome

C. Caron de Fromentel, T. Voeltzel, X. Thomas, 2018, Cell Death & Disease.

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.

C Chastang, R. Bouabdallah, C. Chastang, 1997, The New England journal of medicine.

Chemotherapy in non-Hodgkin's malignant lymphomas according to potential evolutive groups.

J. Sotto, M. Michallet, B. Lachet, 1978, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia

C. Dumontet, X. Thomas, M. Elhamri, 2014, Leukemia & lymphoma.

Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies.

M. Robin, P. Chevallier, I. Yakoub-Agha, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM

R. Porcher, H. Dombret, M. Robin, 2015, Leukemia.

Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC)

P. Chevallier, I. Yakoub-Agha, J. Bay, 2021, Journal of Cancer Research and Clinical Oncology.

Improved Outcome in Young Children Compared to Adolescents and Adults After Allogeneic Hematopoietic Stem Cell Transplant for Acute Myeloid Leukemia: a Retrospective Study From Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC) (SFGM-TC)

P. Chevallier, I. Yakoub-Agha, J. Bay, 2021 .

Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

J. Esteve, C. Craddock, M. Labopin, 2017, Haematologica.

Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT 3-ITD ; a study from the Acute Leukemia Working

J. Esteve, C. Craddock, M. Labopin, 2017 .

Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1.

C. Craddock, M. Labopin, P. Chevallier, 2017, Blood advances.

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.

H. Dombret, B. Quesnel, P. Hérait, 2016, The Lancet. Haematology.

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

R. Bataille, B. Grosbois, I. Yakoub-Agha, 2007, Blood.

Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience

G. Salles, A. Plesa, E. Wattel, 2019, Cancers.

Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC.

S. Leprêtre, S. Chevret, F. Davi, 2011, Blood.

High DNA Methyltransferase DNMT3B Levels: A Poor Prognostic Marker in Acute Myeloid Leukemia

G. Salles, A. Plesa, J. Magaud, 2012, PloS one.

Younger donor’s age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

J. Bourhis, I. Yakoub-Agha, D. Blaise, 2012, Haematologica.

IMPACT OF T-CELL DEPLETION ON OUTCOME OF ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR STANDARD-RISK LEUKAEMIAS

D. Blaise, V. Leblond, N. Ifrah, 1987, The Lancet.

TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.

D. Maucort-Boulch, D. Auboeuf, E. Wattel, 2017, Leukemia research.

Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.

M. Tulliez, P. Berthaud, P. Rousselot, 2003, Blood.

Clinical nutrition guidelines of the French Speaking Society of Clinical Nutrition and Metabolism (SFNEP): Summary of recommendations for adults undergoing non-surgical anticancer treatment.

F. Goldwasser, P. Bachmann, M. Vasson, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia.

S. Iacobelli, R. Brand, A. Gratwohl, 2002, Blood.

Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia

J. Sierra, M. Labopin, H. Sengeløv, 2015, Leukemia.

Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group.

D. Blaise, X. Troussard, G. Marit, 1995, Blood.

Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: The EBMT experience

G. Gahrton, G. Juliusson, S. Mackinnon, 2000 .

Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group.

G. Marit, N. Dastugue, D. Leroux, 1995, Leukemia.

Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period

C. Sebban, J. Magaud, X. Thomas, 2001, Leukemia.

Long-Term Survival after Stem Cell Transplant in Adult Acute Lymphoblastic Leukemia

C. Sebban, X. Thomas, M. Michallet, 2003 .

Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation

E. Archimbaud, J. Sotto, M. Michallet, 1999, Bone Marrow Transplantation.

Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia

X. Thomas, C. Récher, E. Delabesse, 2018, European journal of haematology.

Epstein-Barr Virus (EBV) Reactivation, Its Treatment with Rituximab and Their Impact on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

X. Thomas, C. Rioufol, B. Lina, 2016 .

A matched case-control study of toxoplasmosis after allogeneic haematopoietic stem cell transplantation: still a devastating complication.

G. Salles, X. Thomas, M. Rabodonirina, 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

First Results of a Prospective Study on Erythropoietin Biosimilar (Epoetin zeta) Use in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

X. Thomas, F. Barraco, F. Nicolini, 2015 .

Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia

R. Écochard, X. Thomas, Q. Le, 2006, European journal of haematology.

Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)

M. Abecassis, P. Richardson, F. Baron, 2015, Bone Marrow Transplantation.

French Intensive Care Society, International congress – Réanimation 2016

Paul P. Tallon, Stéphane Huot, B. Souweine, 2016, Annals of Intensive Care.

M. Bernard, P. Chevallier, I. Yakoub-Agha, 2016, Haematologica.

Intensive chemotherapy versus bone marrow transplantation in pediatric acute myeloid leukemia : a matter of controversies

D. Blaise, J. Reiffers, N. Ifrah, 2001 .

Mobilisation of healthy donors with lenograstim and transplantation of HLA-genoidentical blood progenitors in 54 patients with hematological malignancies: a pilot study

D. Blaise, C. Chabannon, D. Maraninchi, 1998, Bone Marrow Transplantation.

Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial.

S. Chevret, P. Chevallier, I. Yakoub-Agha, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial

M. Labopin, P. Chevallier, D. Blaise, 2014, Haematologica.

High rate of long-term survivals in AML treated by chemotherapy and androgenotherapy: a pilot study.

J. Sotto, M. Michallet, R. Berthier, 1980, Cancer.

Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.

P. Cony-Makhoul, J. Magaud, S. Hayette, 2011, Leukemia research.

RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT

J. Esteve, J. Sierra, F. Baron, 2016, Oncotarget.

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

E. Kimby, J. Gribben, E. Montserrat, 2014, Blood.

Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation

J. Bourhis, D. Blaise, M. Mohty, 2003, Leukemia.

Prospective randomized study of GVHD prevention using an anti IL2 receptor (CD25) MoAb after allogeneic bone marrow transplantation (BMT).

D. Olive, D. Blaise, J. Reiffers, 1991, Bone marrow transplantation.

M. Labopin, M. Mohty, E. Deconinck, 2010 .

HLA Matching Is More Critical Than CMV Matching in Predicting Non-Relapse-Mortality of Patients Undergoing HSCT From An Unrelated Donor: A Retrospective Monocenter Study.

X. Thomas, F. Barraco, F. Nicolini, 2009 .

High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma

D. Blaise, A. Nagler, M. Mohty, 2008, Haematologica.

Role of splenectomy in incidence and severity of acute graft-versus-host disease: a multicenter study of 157 patients.

J. Reiffers, C. Chabannon, J. Bosson, 1991, Bone marrow transplantation.

Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy.

M. Robin, P. Chevallier, I. Yakoub-Agha, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation.

M. Labopin, A. Bosi, F. Locatelli, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second A llogeneic B one M arrow T ransplantation i n A cute Leukemia: R esults o f a S urvey b y t he E uropean Cooperative G roup f or B lood a nd M arrow T ransplantation

J. Sierra, M. Labopin, A. Bosi, 2001 .

Double umbilical cord blood transplantation for hematological malignancies: a long-term analysis from the SFGM-TC registry.

M. Robin, I. Yakoub-Agha, D. Blaise, 2013, Experimental hematology.

Cost-effectiveness and clinical outcomes of double versus single cord blood transplantation in adults with acute leukemia in France

M. Labopin, I. Yakoub-Agha, D. Blaise, 2014, Haematologica.

Occurrence of graft‐versus‐host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT

F. Baron, M. Labopin, P. Chevallier, 2018, Journal of internal medicine.

Chronic graft-versus-host disease features in double unit cord blood transplantation according to National Institutes of Health 2005 cGVHD Consensus criteria

P. Rohrlich, G. Basak, H. Veelken, 2018, Bone Marrow Transplantation.

Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome.

K. Baumstarck, A. Loundou, I. Yakoub-Agha, 2016, Blood.

Double Cord Blood Transplantation: Incidence, Organ Involvement and Risk Factors of Acute Graft Versus Host Disease. a Retrospective Analysis on Behalf of Eurocord, ALWP and Cqwp-EBMT

J. Bourhis, C. Craddock, M. Labopin, 2014 .

Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs

B. Esterni, D. Blaise, M. Mohty, 2012, Bone Marrow Transplantation.

M. Labopin, M. Mohty, E. Deconinck, 2013, Transplantation.

Impact of Antithymocyte Globulins on Patient Outcome after Myeloablative Bone Marrow Stem Cell Transplantation from HLA 10/10-Matched Unrelated Donor: A Report from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC)

I. Yakoub-Agha, M. Mohty, J. Bay, 2014 .

Extracorporeal photopheresis for GVHD prophylaxis after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation: a prospective multicenter phase 2 study

I. Yakoub-Agha, P. Rohrlich, F. Barraco, 2018, Leukemia & lymphoma.

Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients.

D. Blaise, M. Mohty, P. Moreau, 2013, Experimental hematology.

Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy

J. Bourhis, I. Yakoub-Agha, M. Mohty, 2013, Haematologica.

Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.

J. Bourhis, I. Yakoub-Agha, P. Moreau, 2006, Blood.

Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation

J. Bourhis, G. Mufti, F. Baron, 2018, Bone Marrow Transplantation.

Lymphodepletive effects of rabbit anti-pig thymocyte globulin in neonatal swines.

I. Mollet, J. Dubernard, A. Gazarian, 2016, Transplant immunology.

Higher Doses of Antithymocyte Globulin (ATG) Increase the Risk of Relapse in Acute Myeloid Leukemia (AML) Patients Undergoing Matched Related Donor Allogeneic Transplantation in First Complete Remission (CR1): An Analysis from the Acute Leukemia Working Party of EBMT

J. Bourhis, F. Baron, M. Labopin, 2014 .

Severe chronic primary neutropenia in adults: report on a series of 108 patients.

É. Oksenhendler, P. Moreau, C. Bellanné-Chantelot, 2015, Blood.

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase

T. Brümmendorf, G. Martinelli, J. Cortes, 2008, Leukemia.

Allogeneic Bone Marrow Transplantation in Chronic Lymphocytic Leukemia: 17 Cases. Report of the EBMT.

A. Gratwohl, A. Moine, S. Brunet, 1991, Leukemia & lymphoma.

[Allogeneic stem cell transplantation from an HLA-haploidentical related donor: SFGM-TC recommendations (part 2)].

P. Chevallier, I. Yakoub-Agha, D. Blaise, 2014, Pathologie-biologie.

Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy

M. Robin, P. Chevallier, I. Yakoub-Agha, 2015, Transplantation.

Treatment options for relapse after autograft in multiple myeloma – report from an EBMT educational meeting

N. Kröger, G. Gahrton, G. Cook, 2017, Leukemia & lymphoma.

Preferential sensitivity of hematopoietic (HPs) and mesenchymal (MPs) progenitors to fludarabine suggests impaired bone marrow niche and HP mobilization

O. Tournilhac, F. Nicolini, M. Michallet, 2008, Leukemia.

Transplant results in adults with Fanconi anaemia

R. Porcher, N. Kröger, M. Aljurf, 2018, British journal of haematology.

European Cooperative Group for Bone Marrow Transplantation Bone marrow transplantation in multiple myeloma: report from the

G. Gahrton, A. Gratwohl, J. Reiffers, 2011 .

An update of prognostic factors for allogeneic bone marrow transplantation in multiple myeloma using matched sibling donors

G. Gahrton, A. Gratwohl, J. Reiffers, 1995, Stem cells.

[Allogeneic stem cell transplantation from an HLA-haploidentical related donor: SFGM-TC recommendations (Part 1)].

P. Chevallier, I. Yakoub-Agha, D. Blaise, 2014, Pathologie-biologie.

Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

J. Bourhis, I. Yakoub-Agha, D. Blaise, 2008, Experimental hematology.

Double reduced-intensity allogeneic hematopoietic stem cell transplantation: a retrospective study from the SFGM-TC.

M. Robin, P. Chevallier, D. Blaise, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic H ematopoietic S tem-Cell T ransplantation A fter Nonmyeloablative P reparative R egimens: I mpact o f Pretransplantati on a nd P osttransplantat ion F actors on O utcome

D. Blaise, P. Moreau, X. Thomas, 2001 .

Kinetics of Chimerism Conversion to Total Donor Profile: Impact on Transplant Outcome after Reduced Intensity Conditioning Allogeneic Transplantation.

A. Thiébaut, F. Nicolini, V. Dubois, 2004 .

Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor

D. Blaise, M. Mohty, J. Bay, 2012, Annals of Hematology.

Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced‐intensity conditioning regimens

X. Thomas, F. Nicolini, V. Dubois, 2005, British journal of haematology.

Mixed Chimerism at Three Months after Allogeneic Hematopoietic Stem Cell Transplantation Is a Significant Predictor of Disease Relapse in High-Risk Acute Myeloid Leukemia Patients in First Complete Remission

X. Thomas, I. Mollet, F. Barraco, 2015 .

Management of psychiatric complications in unrelated donor before unrelated peripheral hematopoietic stem cell collections

M. Saoud, E. Wattel, J. Jouet, 2016, Journal of blood medicine.

Allogeneic bone marrow transplantation in patients with multiple myeloma

M. Gore, G. Gahrton, A. Gratwohl, 1989, European journal of haematology. Supplementum.

Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies

C. Scheibenbogen, S. Sánchez-Ramón, C. Agostini, 2019, European journal of haematology.

Bone marrow transplantation for chronic lymphocytic leukemia.

S. Tura, G. Rosti, G. Bandini, 1991, Bone marrow transplantation.

Total donor chimerism with bone marrow GVHD after multivisceral transplantation

J. Dumortier, A. Plesa, A. Eljaafari, 2018, American journal of hematology.

Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire

P. Chevallier, M. Mohty, J. Cassuto, 2016, Transplantation.

Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative study

M. Robin, Y. Bertrand, J. Bay, 2013, Bone Marrow Transplantation.

Prospective Study Comparing Idarubicin and Daunorubicin in Elderly Patients with Acute Myeloid Leukemia

P. Cony-Makhoul, J. Reiffers, P. Hurteloup, 1992 .

A. Ganser, N. Kröger, M. Labopin, 2016, Journal of Hematology & Oncology.

Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML

H. Dombret, C. Preudhomme, P. Fenaux, 2012, Bone Marrow Transplantation.

Splenectomy during chronic lymphocytic leukemia

B. Pégourié, J. Sotto, M. Michallet, 1987, Cancer.

Management of CLL patients after chlorambucil therapy. Special value of a second RAI staging.

J. Arvieux, J. Sotto, M. Michallet, 1980, European journal of cancer.

Pomalidomide Plus Low-Dose Dexamethasone In Relapsed Or Refractory Multiple Myeloma (RRMM) With Deletion (del)17p and/Or Translocation t(4;14)

B. Pégourié, O. Decaux, P. Moreau, 2013 .

Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation

B. Pégourié, S. Iacobelli, G. Gahrton, 2010 .

Prophylactic Extracorporeal Photopheresis for Gvhd Prevention after Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation from Identical Siblings and 10/10 HLA Unrelated Hematopoietic Stem Cells Donors

I. Yakoub-Agha, P. Rohrlich, F. Barraco, 2014 .

Centre characteristics and procedure‐related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT)

H. Putter, J. Delgado, N. Kröger, 2017, British journal of haematology.

Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study.

D. Blaise, M. Mohty, J. Bay, 2013, Experimental hematology.

A comparison of flow cytometry detection of minimal residual disease and chimerism kinetics in chronic lymphocytic leukemia patients after allogeneic hematopoietic stem cell transplantation

A. Plesa, C. Dumontet, X. Thomas, 2011 .

trial from the SFGM-TC and GFLLC for chronic lymphocytic leukemia: a multicenter, randomized, controlled Autologous stem cell transplantation as a first-line treatment strategy

S. Leprêtre, S. Chevret, V. Leblond, 2011 .

Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia.

P. Feugier, S. Leprêtre, B. Grosbois, 2004, Blood.

Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

M. Robin, I. Yakoub-Agha, M. Mohty, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Role of age and hematopoietic cell transplantation-specific comorbidity index in myelodysplastic patients undergoing an allotransplant. A retrospective study from the CMWP (Chronic Malignancies Working Party) of the EBMT.

R. Porcher, A. Ganser, N. Kröger, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term persistent lymphopenia in hematopoietic stem cell donors after donation for donor lymphocyte infusion.

E. Wattel, F. Nicolini, O. Hequet, 2004, Experimental hematology.

Reassessing autotransplantation for acute myeloid leukaemia in first remission – a matched pair analysis of autologous marrow vs peripheral blood stem cells

S. Singhal, J. Mehta, M. Labopin, 2004, Bone Marrow Transplantation.

lymphocytic leukemia treatment on peripheral blood stem cell mobilization in B-cell chronic Impact of frontline fludarabine and cyclophosphamide combined

S. Leprêtre, B. Grosbois, A. Delmer, 2013 .

Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia

S. Montoto, P. Dreger, J. Passweg, 2019, Bone Marrow Transplantation.

Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: 17 cases. Report from the EBMTG.

A. Gratwohl, S. Brunet, N. Milpied, 1991, Bone marrow transplantation.

Higher percentage of CD34 + CD38− cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia

A. Plesa, C. Dumontet, X. Thomas, 2015, Leukemia & lymphoma.

Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia.

C. Sebban, É. Lepage, J. Reiffers, 1994, Journal of Clinical Oncology.

transplantation: long-term results of a randomized study Chronic graft-versus-host disease after allogeneic blood stem cell

J. Bourhis, D. Blaise, M. Mohty, 2013 .

Prior treatment with alpha interferon does not adversely  affect the outcome of allogeneic transplantation  for chronic myeloid leukaemia

J. Reiffers, O. Reman, N. Ifrah, 2002, British journal of haematology.

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia

H. Dombret, B. Quesnel, P. Hérait, 2014 .

Allogeneic hematopoietic stem cell transplant for hematological malignancies from mismatched 9/10 human leukocyte antigen unrelated donors: comparison with transplants from 10/10 unrelated donors and human leukocyte antigen identical siblings

X. Thomas, F. Barraco, F. Nicolini, 2015, Leukemia & lymphoma.

J. Bourhis, P. Chevallier, I. Yakoub-Agha, 2018, American journal of hematology.

Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia.

X. Thomas, E. Archimbaud, M. Michallet, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Skin allograft for severe chronic GvHD

O. Damour, V. Dubois, M. Sobh, 2017, Bone Marrow Transplantation.

IL2 in Acute Leukemia

R. Bouabdallah, D. Blaise, J. Reiffers, 1996 .

Allogeneic bone marrow tranplantation for young adult patients with newly diagnosed acute myeloid leukemia: HLA-Matched sibling donor availability does not improve treatment ouctome

X. Thomas, C. Charrin, Q. Le, 2000 .

Continuous-infusion carboplatin in combination with idarubicin or mitoxantrone for high-risk acute myeloid leukemia: a randomised phase II study.

E. Wattel, X. Thomas, E. Archimbaud, 1999, Leukemia & lymphoma.

A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia.

R. Bouabdallah, D. Olive, D. Blaise, 1998, Leukemia & lymphoma.

New Quantitative Method to Identify NPM1 Mutations in Acute Myeloid Leukaemia

J. Magaud, S. Hayette, F. Nicolini, 2013, Leukemia research and treatment.

MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs

O. Decaux, A. Lamblin, P. Moreau, 2013, Thrombosis and Haemostasis.

Risk assessment in adult acute lymphoblastic leukaemia before early haemopoietic stem cell transplantation with a geno-identical donor: an easy clinical prognostic score to identify patients who benefit most from allogeneic haemopoietic stem cell transplantation

M. Labopin, D. Blaise, J. Reiffers, 2003, Leukemia.

BMT IN MULTIPLE MYELOMA — PROGNOSTIC FACTORS

A. Hagenbeek, A. Gratwohl, J. Reiffers, 2017 .

multiple myeloma autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo followed by a dose-reduced allograft (IFM99-03 trial) with tandem Prospective comparison of autologous stem cell transplantation

G. Marit, J. Harousseau, M. Attal, 2013 .

Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol.

R. Bataille, I. Yakoub-Agha, P. Moreau, 2006, Blood.

Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial.

J. Bourhis, H. Dombret, C. Preudhomme, 2007, Blood.

Effect of Priming with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Younger Adults with Newly Diagnosed Acute Myeloid Leukemia (AML): A Trial by the Acute Leukemia French Association (ALFA) Group.

J. Bourhis, H. Dombret, B. Quesnel, 2005 .

How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome.

P. Chevallier, A. Bazarbachi, C. Pautas, 2017, Current research in translational medicine.

É. Luporsi, F. Maloisel, P. Soubeyran, 2014, BMC Cancer.

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

C. Preudhomme, M. Tulliez, S. Hayette, 2006 .

Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years

M. Labopin, P. Chevallier, A. Nagler, 2015, Bone Marrow Transplantation.

T. G. S. Group, É. Luporsi, F. Maloisel, 2014, BMC Cancer.

[Assessment and management of post-transplant iron overload: Guidelines of the Francophone Society of Marrow Transplantation and Cellular Therapy (SFGM-TC)].

P. Chevallier, I. Yakoub-Agha, P. Rohrlich, 2016, Bulletin du Cancer.

Real-Life Rates of Disease Monitoring in Clinical Practice in Europe: The “Unmet Needs in CML and Ph+ALL” (UNIC) Study.

M. Intorcia, G. Ossenkoppele, G. Verhoef, 2007 .

Imatinib Resistance and/or Intolerance in Clinical Practice in Europe: The “Unmet Needs in CML and Ph+ALL” (UNIC) Study.

G. Ossenkoppele, G. Verhoef, E. Morra, 2007 .

Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial

P. Chevallier, D. Blaise, M. Mohty, 2015, Haematologica.

Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph‐negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation

M. Labopin, I. Yakoub-Agha, A. Nagler, 2018, American journal of hematology.

Short-term pharmacokinetic study of mycophenolate mofetil in neonatal swine.

J. Dubernard, A. Gazarian, M. Sobh, 2014, Transplantation proceedings.

AUTOGRAFTING FOR CHRONIC GRANULOCYTIC LEUKAEMIA IN ACCELERATED PHASE

J. Reiffers, P. Hervé, D. Maraninchi, 1985, British journal of haematology.

Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Sociét Française de Greffe de Moelle.

P. Gaulard, N. Ifrah, H. Esperou, 1999, British journal of haematology.

A Randomized Single−Blind Study of Extracorporeal Photopheresis with UVADEX® Plus Conventional Therapy (CT) Compared to CT Alone in Chronic GVHD.

L. Bouzas, A. Elmaagacli, H. Greinix, 2006 .

Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle.

C. Chastang, J. Reiffers, X. Troussard, 1996, Blood.

Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA.

H. Dombret, I. Yakoub-Agha, E. Deconinck, 2017, Leukemia research.

Incidence of Hospital-Acquired Pneumonia, Bacteraemia and Urinary Tract Infections in Patients with Haematological Malignancies, 2004–2010: A Surveillance-Based Study

P. Vanhems, M. Michallet, T. Bénet, 2013, PloS one.

Hevylite® to Monitor Response to Therapy in Multiple Myeloma

B. Pégourié, O. Decaux, P. Moreau, 2014 .

Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.

J. Rossi, R. Bouabdallah, D. Blaise, 2000, European cytokine network.

Reduction of invasive aspergillosis incidence among immunocompromised patients after control of environmental exposure.

P. Vanhems, X. Thomas, A. Thiébaut, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Allogeneic Bone Marrow Transplantation in Chronic Lymphocytic Leukemia

C. Rozman, P. Rowlings, M. Michallet, 1996, Annals of Internal Medicine.

Final Results of a Prospective Randomized Multicenter Phase III Trial Comparing Treosulfan/Fludarabine to Reduced Intensity Conditioning with Busulfan/Fludarabine Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Elderly or Comorbid Patients with Acute Myeloid Leukemia or Myelodysplasti

P. Dreger, C. Junghanss, F. Ciceri, 2017 .

Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate‐dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy

C. Gisselbrecht, C. Sebban, X. Troussard, 1990, Cancer.

Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma.

I. Yakoub-Agha, M. Mohty, S. Leyvraz, 2008, Blood.

É. Luporsi, P. Soubeyran, J. Kurtz, 2016, OncoTargets and therapy.

Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis : a Preliminary Descriptive Report Of The JAK ALLO Study, a Phase II Trial Sponsored By Goelams-FIM In Collaboration With The Sfgmtc

R. Porcher, M. Robin, I. Yakoub-Agha, 2013 .

Outcomes After Unrelated Cord Blood Transplantation For Adults With Primary Or Secondary Myelofibrosis: A Retrospective Study On Behalf Of Eurocord and Chronic Malignancy Working Party-EBMT

N. Kröger, J. Sierra, M. Robin, 2013 .

Outcomes After Double Unit Unrelated Cord Blood Transplantation (UCBT) Compared with Single UCBT In Adults with Acute Leukemia In Remission. An Eurocord and ALWP Collaboration Study

M. Labopin, I. Yakoub-Agha, M. Mohty, 2010 .

Treatment of acute myeloid leukemia in elderly patients: the influence of maintenance therapy (BGM 84 protocol).

J. Reiffers, G. Marit, D. Maraninchi, 1990, Nouvelle revue francaise d'hematologie.

Conditioning‐based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991‐2012) on behalf of EBMT CMWP

N. Kröger, S. Iacobelli, I. Yakoub-Agha, 2019, European journal of haematology.

Leukocytosis and circulating blasts in older adults with newly diagnosed acute myeloid leukemia: are they valuable factors for therapeutic decision-making?

C. Dumontet, X. Thomas, M. Elhamri, 2011, Clinical lymphoma, myeloma & leukemia.

Prognostic Index for Older Adult Patients with Newly Diagnosed Acute Myeloid Leukemia: The Edouard Herriot Hospital Experience

E. Wattel, C. Dumontet, X. Thomas, 2008 .

Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia

A. Plesa, C. Dumontet, X. Thomas, 2008, Cancer.

Is there a place for blood stem-cell transplantation for the younger adult patient with acute myelogenous leukemia? BGMT Group.

J. Reiffers, M. Attal, A. Stoppa, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT

S. Montoto, N. Kröger, P. Chevallier, 2019, Bone Marrow Transplantation.

HLA‐DRB3/4/5 mismatches are associated with increased risk of acute GVHD in 10/10 matched unrelated donor hematopoietic cell transplantation

R. Porcher, P. van Endert, P. Chevallier, 2018, American journal of hematology.

Maintenance Treatment with Thalidomide after Autologous Transplantation for Myeloma : First Analysis of a Prospective Randomized Study of the Intergroupe Francophone du Myelome (IFM 99 02).

B. Coiffier, J. Bourhis, S. Leyvraz, 2004 .

Haploidentical transplant in patients with myelodysplastic syndrome.

R. Porcher, N. Kröger, J. Sierra, 2017, Blood advances.

Proportion of long‐term event‐free survivors and lifetime of adult patients not cured after a standard acute lymphoblastic leukemia therapeutic program

R. Écochard, X. Thomas, Q. Le, 2007, Cancer.

Trisomy 8 as sole anomaly or with other clonal aberrations in acute myeloid leukemia: impact on clinical presentation and outcome.

X. Thomas, M. Elhamri, I. Tigaud, 2007, Leukemia research.

Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen for elderly patients (60 years and older) with hematologic malignancies using unrelated donors: a retrospective study from the French society for stem cell transplantation (SFGM-TC)

I. Yakoub-Agha, D. Blaise, M. Mohty, 2016, Haematologica.

The K247R Substitution in ABL Tyrosine Kinase Domain Is Not a Mutation Leading to Imatinib Resistance but a Polymorphism Rarely Present in CML Patients and in Normal Subjects.

J. Cayuela, J. Magaud, X. Thomas, 2005 .

Dasatinib-induced acute hepatitis

L. Cotte, F. Nicolini, A. Bonvin, 2008, Leukemia & lymphoma.

Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group.

H. Dombret, S. Leprêtre, R. Gressin, 2021, Clinical lymphoma, myeloma & leukemia.

Prospective Randomized Comparison of Reduced Intensity (FLU-BU-ATG) and Non-Myeloablative (FLU-TBI) Conditioning for Genoidentical Allo-SCT: a Clinical and economical Multicenter Itac Study.

D. Blaise, M. Mohty, J. Bay, 2009 .

Myeloablative unrelated cord blood transplantation in adolescents and young adults with acute leukemia.

I. Yakoub-Agha, M. Aljurf, R. Hough, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

G-CSF-induced aneuploidy does not affect CD34+ cells and does not require cell division.

J. Pallandre, E. Deconinck, P. Tiberghien, 2010, Blood.

Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK‐NUP214 shows a favourable outcome when performed in first complete remission

J. Esteve, J. Sierra, M. Labopin, 2020, British journal of haematology.

Influence of cigarette smoking on the presentation and course of acute myeloid leukemia.

X. Thomas, C. Charrin, Q. Le, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

A prospective randomized study comparing the efficacy of Timentin alone or in combination with amikacin in the treatment of febrile neutropenic patients.

J. Stahl, J. Sotto, M. Micoud, 1986, The Journal of antimicrobial chemotherapy.

Fatal Nosocomial Legionella pneumophila Infection Due to Exposure to Contaminated Water From a Washbasin in a Hematology Unit

P. Vanhems, J. Etienne, F. Nicolini, 2008, Infection Control & Hospital Epidemiology.

Acute graft-versus-host disease, invasive aspergillosis and Clostridium difficile colitis after peripheral blood stem cell transplantation: A complex network of causalities and a challenge for prevention.

N. Khanafer, P. Vanhems, A. Neuraz, 2015, Anaerobe.

Patterns of Sequelae in Women with a History of Localized Breast Cancer: Results from the French VICAN Survey

B. Fervers, F. Reyal, L. Delrieu, 2021, Cancers.

Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML)

M. Baccarani, J. Cortes, C. Chuah, 2013 .

Safety and Efficacy Study of Subcutaneous Homoharringtonine (SC HHT) in Imatinib (IM)-Resistant Chronic Myeloid Leukemia (CML) with the T315I Mutation - Initial Report of a Phase II Trial.

H. Kantarjian, J. Cortes, H. Khoury, 2007 .

[Evaluation of three types of empirical antibiotherapy in patients with febrile neutropenia: imipenem-cilastatin versus ceftazidime-vancomycin versus ticarcillin-amikacin-vancomycin].

J. Brion, J. Stahl, M. Micoud, 1992, Pathologie-biologie.

Hepatomegaly and fever at the time of neutrophil recovery revealing L-asparaginase toxicity in the treatment of acute lymphoblastic leukemia

F. Berger, X. Thomas, J. Saison, 2014, The American journal of case reports.

Nutrition chez le patient adulte atteint de cancer : introduction

M. Vasson, X. Hébuterne, C. Bouteloup, 2012 .

Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe

P. Chevallier, J. Sanz, J. Cornelissen, 2022, Blood advances.

[Second allogeneic hematopoietic stem cell transplant: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)].

I. Yakoub-Agha, M. Michallet, T. Guillaume, 2019, Bulletin du cancer.

[Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)].

P. Chevallier, I. Yakoub-Agha, A. Bazarbachi, 2017, Bulletin du cancer.

Outcomes of graft failure after umbilical cord blood transplantation in acute leukemia: a study from Eurocord and the Acute Leukemia Working Party of the EBMT

J. Bourhis, F. Baron, M. Labopin, 2023, Bone Marrow Transplantation.

Can a reduced-intensity conditioning regimen cure blastic plasmacytoid dendritic cell neoplasm?

F. Jardin, P. Chevallier, I. Yakoub-Agha, 2017, Blood.

[Effectiveness of combined vancomycin and pefloxacine in gastrointestinal decontamination for preventing infections after chemotherapy-induced bone marrow aplasia. A randomized double-blind study].

X. Thomas, A. Thiébaut, E. Archimbaud, 2000, Presse medicale.

Cytogenetic and molecular testing in patients with chronic myeloid leukemia (CML) in a prospective observational study (SIMPLICITY).

J. Cortes, R. Paquette, H. Khoury, 2014 .

Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with T-Cell Acute Lymphoblastic Leukemia: A Survey From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

J. Esteve, M. Labopin, I. Yakoub-Agha, 2012 .

Purification and cryopreservation of granulomonocytic colony forming cells (GM-CFC) from the blood of patients with chronic granulocytic leukemia (CGL) for autologous transplantation.

J. Arvieux, J. Sotto, D. Thevenon, 1982, Experimental hematology.

Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients Aged ≥60 Years: a Retrospective Study of 629 Patients From the Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC).

P. Chevallier, I. Yakoub-Agha, D. Blaise, 2009 .

Lenalidomide After Autologous Transplantation for Myeloma: First Analysis of a Prospective, Randomized Study of the Intergroupe Francophone Du Myelome (IFM 2005 02).

S. Leyvraz, P. Moreau, H. Avet-Loiseau, 2009 .

Candida albicans and non-Candida albicans fungemia in an institutional hospital during a decade.

L. Argaud, B. Allaouchiche, C. Guérin, 2013, Medical mycology.

The 3rd National Festival & International Congress on Stem Cell & Regenerative Medicine

A. Seifalian, H. Ahmadieh, H. Poustchi, 2018, BioImpacts : BI.

Estimation of the incubation period of invasive aspergillosis by survival models in acute myeloid leukemia patients.

N. Voirin, P. Vanhems, Marie-Christine Nicolle, 2013, Medical mycology.

Autologous HSCT for Ph-Positive Adult Acute Lymphoblastic Leukemia: A Curative Option in the Era of Tyrosine Kinase Inhibitors? an Analysis From the Acute Leukemia Working Party of the EBMT

M. Labopin, M. Mohty, G. Socié, 2012 .

Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic‐phase CML in clinical practice: 3‐year European SIMPLICITY data

R. Paquette, C. Gambacorti-Passerini, R. Hehlmann, 2020, European journal of haematology.

Final Evaluation of a Clinical Phase III Trial Comparing Treosulfan to Busulfan-Based Conditioning Therapy Prior to Allogeneic Hematopoietic Stem Cell Transplantation of Adult Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients Ineligible to Standard Myeloablative Regimens

D. Niederwieser, P. Dreger, E. Holler, 2019, Biology of Blood and Marrow Transplantation.

Oral Mucositis After Allogeneic Hematopoietic Stem Cell Transplantation: Important Impact Of The Presence Of Aciclovir-Resistant Herpes Simplex Virus (HSV-1) On Its Occurrence

X. Thomas, B. Lina, V. Escuret, 2013 .

H. Dombret, P. Fenaux, S. Thépot, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[Budd-Chiari syndrome in paroxysmal nocturnal hemoglobinuria. Report of a case and review of the literature (author's transl)].

C. Létoublon, J. Sotto, M. Michallet, 1979, Gastroenterologie clinique et biologique.

B. Lebeau, M. Mallaret, P. Ambroise‐Thomas, 1993, Presse medicale.

Chronic disseminated candidiasis and acute leukemia: Impact on survival and hematopoietic stem cell transplantation agenda.

X. Thomas, M. Le Maréchal, M. Michallet, 2018, Medecine et maladies infectieuses.

PV-0042: Fractionated-TBI schedules prior to allograft: Study from the Acute Leukemia Working Party (EBMT)

M. Labopin, I. Yakoub-Agha, A. Nagler, 2017 .

The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial

A. Vekhoff, P. Chevallier, M. Mohty, 2018, Blood.

Current IST-free/relapse-free survival as a new endpoint after allogeneic hematopoietic stem cell transplantation

A. Signori, F. Barraco, M. Sobh, 2020, Annals of Hematology.

Allogeneic donor bone marrow cells recovery and infusion after allogeneic face transplantation from the same donor

B. Devauchelle, J. Dubernard, E. Morelon, 2008, Bone Marrow Transplantation.

Reduced Intensity Versus Myelo-Ablative Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Retrospective Study of the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC)

F. Jardin, P. Chevallier, I. Yakoub-Agha, 2015 .

Updated Analysis of Hematopoietic Stem Cell Transplantations after Reduced Intensity Conditioning Regimen (RIC HSCT) for Hematological Malignancies from the Société Française de Greffe de Moelle Osseuse et de Thérapie Cellulaire (SFGM-TC) Registry.

D. Blaise, M. Mohty, H. Esperou, 2005 .

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy

L. Fornecker, C. Récher, K. Laribi, 2022, Cancer Medicine.

A new signaling cascade linking BMP4, BMPR1A, ΔNp73 and NANOG impacts on stem-like human cell properties and patient outcome

C. Caron de Fromentel, T. Voeltzel, X. Thomas, 2018, Cell Death & Disease.

Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients

A. Vekhoff, P. Chevallier, M. Mohty, 2021, Nature Communications.

Parenteral nutrition in patients with leukemia and non-Hodgkin malignant lymphoma under chemotherapy.

M. Michallet, A. Guignier, D. Hollard, 1979, JPEN. Journal of parenteral and enteral nutrition.

[Allogeneic haematopoietic cell transplantation for diffuse large B cell lymphoma: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

G. Salles, I. Yakoub-Agha, F. Morschhauser, 2017, Bulletin du cancer.

Graft-versus-host disease and graft-versus-leukemia.

M. Michallet, 1996, Hematology and cell therapy.

Treatment of Adult Acute Lymphoblastic Leukemia Long Term Results of a Prospective Study: LALA 87

A. Delannoy, C. Sebban, É. Lepage, 2001 .

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus

E. Kimby, E. Montserrat, W. Wiktor-Jedrzejczak, 2007, Leukemia.

Individualised physical activity programme in patients over 65 years with haematological malignancies (OCAPI): protocol for a single-arm feasibility trial

B. Fervers, G. Millet, L. Delrieu, 2021, BMJ Open.

Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple

I. Yakoub-Agha, G. Marit, J. Harousseau, 2005 .

Long-term Follow-up of a Randomized Trial Comparing the Combination of Cyclophosphamide with Total Body Irradiation or Busulfan as Conditioning Regimen for Patients Receiving Hla- Identical Marrow Grafts for Acute Myeloblastic Leukemia in First Complete Remission

D. Blaise, J. Reiffers, N. Ifrah, 2022 .

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres

G. Gahrton, N. Russell, R. Willemze, 2001, British journal of haematology.

Imatinib use in chronic phase CML in clinical practice: the UNIC study

D. Marin, G. Ossenkoppele, G. Verhoef, 2008 .

Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.

H. Deeg, K. Sullivan, S. Chevret, 2001, Blood.

Acute Graft-Versus-Host Disease: Grade and Outcome in Patients With Chronic Myelogenous Leukemia

A. Bosi, M. Boogaerts, A. Bacigalupo, 2017 .

Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia.

A. Baruchel, G. Leverger, J. Reiffers, 1992, Blood.

Clinical outcome of therapy‐related acute myeloid leukemia patients. Real‐life experience in a University Hospital and a Cancer Center in France

A. Plesa, S. Hayette, I. Tigaud, 2023, Cancer medicine.

Impact on Transplant Outcome of Karyotyping Analysis in Apheresis Products for Autologous PBSC Transplantation in De Novo Acute Leukemias (AL).

X. Thomas, I. Tigaud, C. Charrin, 2004 .

J. Bourhis, I. Yakoub-Agha, P. Moreau, 2006, Blood.

Autologous Hematopoietic Stem Cell Transplantation (autoHSCT) in CLL: First Results of An EBMT Randomized Trial Comparing Autotransplant Versus Wait and Watch.

R. Brand, M. Hallek, A. Gratwohl, 2009 .

University of Birmingham Allogeneic stem cell transplantation benefits for patients 60 years with acute myeloid leukemia and FLT3 internal tandem duplication:

J. Esteve, M. Labopin, P. Chevallier, 2018 .

Evaluation of gemcitabine in relapsed or refractory multiple myeloma.

C. Dumontet, X. Leleu, T. Facon, 2004, Haematologica.

Preventive Versus Curative Platelet Transfusion Strategies in the Treatment of Acute Myeloid Leukemia Patients: A Comparative Study

X. Thomas, J. Rey, N. Vey, 2014 .

A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology

P. Mintz, P. Rebulla, G. Escolar, 2010, Transfusion.

Short- and long-term outcomes in onco-hematological patients admitted to the intensive care unit with classic factors of poor prognosis

L. Argaud, M. Simon, T. Baudry, 2016, Oncotarget.

Pharmacogenomic Factors Such as the Expression of Imatinib Transporters (OCT-1, ABCB-1 and ABCG-2) at Diagnosis, OCT-1 SNPs, and Steady-State Imatinib and Desmethyl-Imatinib Trough Plasma Levels in De Novo Chronic Phase Chronic Myelogenous Leukemia, May Influence Disease Response to Imatinib

J. Magaud, S. Hayette, I. Tigaud, 2008 .

The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis.

Martin C. Müller, I. Dufva, G. Martinelli, 2010 .

Higher percentage of CD34 + CD38− cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia

A. Plesa, C. Dumontet, X. Thomas, 2015, Leukemia & lymphoma.

Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1.

C. Craddock, M. Labopin, P. Chevallier, 2017, Blood advances.

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

Martin C. Müller, I. Dufva, D. Marin, 2013, Haematologica.

Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system

J. Gangneux, M. Michallet, P. Berger, 2011, Journal of medical economics.

Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study.

D. Parenti, A. Elmaagacli, K. van Besien, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

HHV-6 infection after allogeneic hematopoietic stem cell transplantation: From chromosomal integration to viral co-infections and T-cell reconstitution patterns.

X. Thomas, V. Escuret, F. Barraco, 2016, The Journal of infection.

INTENSIVE INDUCTION CHEMOTHERAPY IN ELDERLY PATIENTS

J. Reiffers, P. Hurteloup, A. Stoppa, 1992 .

Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation.

N. Mahlaoui, Y. Bertrand, A. Thiébaut, 2012, The Journal of antimicrobial chemotherapy.

Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009

N. Voirin, P. Vanhems, X. Thomas, 2011, Haematologica.

A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule

X. Thomas, M. Elhamri, F. Barraco, 2010, Hematology.

S. Montoto, N. Kröger, A. Nagler, 2018, Bone Marrow Transplantation.

Allogeneic stem cell transplantation (allo-SCT) in T-cell lymphomas: A French national survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

C. Volteau, D. Blaise, N. Ifrah, 2007 .

High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies.

E. Kimby, E. Montserrat, S. Stilgenbauer, 2018, Blood.

The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry

R. Brand, J. Finke, N. Russell, 2010, Leukemia.

[Assessment and management of post-transplant iron overload: Guidelines of the Francophone Society of Marrow Transplantation and Cellular Therapy (SFGM-TC)].

P. Chevallier, I. Yakoub-Agha, P. Rohrlich, 2016, Bulletin du cancer.

In Vitro Toxicity of Fludarabine on Normal Bone Marrow (BM) Progenitors Suggests Its Involvement in the Impairment of Hematopoietic Progenitor (HP) Mobilization.

V. Maguer-Satta, O. Tournilhac, M. Berger, 2007 .

The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants

N. Kröger, S. Iacobelli, A. Zander, 2005, Bone Marrow Transplantation.

Comparison of Mobilized Peripheral Blood Stem Cells Versus Unmanipulated Bone Marrow Haploidentical Transplantation Using Post-Transplant Cyclophosphamide: A Retrospective Study of SFGM-TC in 176 Patients

I. Yakoub-Agha, L. Mannone, E. Deconinck, 2017 .

P. Moreau, H. Avet-Loiseau, G. Marit, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of upfront tandem autologous–allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma